Promega Corporation pledged $3 million to the Catalyst Science Fund

| By | Biotechnologies, R&D
0
122

Promega Corporation, a leading provider of biological and pharmacy products, secured $3 million over three years to the Revive & Restore Catalyst Science Fund for support the exploration of new solutions for confronting significant environmental challenges.

The fund is designed to identify and develop advanced techniques of genetic rescue and to bring new tools to conservation work in order to enhance biodiversity. The organization together academic and commercial labs that are advancing the science with conservation practitioners working in the field to develop innovative conservation solutions.

The Catalyst Science Fund will invest primarily in proof of concept projects applied toward high impact solutions to conservation challenges. Supported research will aim to produce actionable science with significant conservation benefits and broad applicability for creating innovative solutions for endangered species and threatened ecosystems. Projects will be reviewed by a distinguished Catalyst Science Advisory comprised of recognized leaders in biotechnology and conservation.

Traditional conservation tools can be limited in addressing global challenges like climate change and current threats to wildlife and ecosystems are demanding innovative approaches. Advances in biotechnology, which have transformed medicine and agriculture, provide fertile ground for transformative breakthroughs in conservation practice. Revive & Restore has identified the opportunity to catalyze innovative science-based solutions for seemingly intractable conservation problems by leveraging and adapting emerging powerful genomic and biotechnology tools.

The Catalyst Science Fund will build on the strengths of both organizations, including a network of scientists and conservationists to provide diverse insights into opportunities presented by recent biotech advances, as well as entrepreneurial expertise and perspective to make the most strategic investments to advance the development of the field.

Promega Corporation is a leading manufacturer of enzymes and other products for biotechnology and molecular biology with a portfolio covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity. Founded in 1978, the company is headquartered in Madison (USA) with branches in 16 countries and over 50 global distributors. This year, Promega Corporation marks its first 40 years of supporting the life sciences industry.